It seems that there's no finish line for Donald Trump's tariffs.

The pharmaceuticals industry, which managed to get off lightly until now, eventually couldn't escape the arrow of fate.

From October 1, the US will start collecting 100% import duty on all branded or patented pharmaceutical products, though it's unclear if these prohibitive levies will be extended at a later date to apply to generic drugs and specialty medicines.

Branded drugs are patent-protected medications sold under a company's name, while generics are their equivalents made after patent expiry, and often cost much lower than patented drugs.

India is the world's pharmaceutical hub, thanks to its dominance in generics drug production. According to trade body Pharmexcil, the US market accounts for over 35% of our total

See Full Page